186 reports of this reaction
2.8% of all DESVENLAFAXINE reports
#5 most reported adverse reaction
COMPLETED SUICIDE is the #5 most commonly reported adverse reaction for DESVENLAFAXINE, manufactured by Actavis Pharma, Inc.. There are 186 FDA adverse event reports linking DESVENLAFAXINE to COMPLETED SUICIDE. This represents approximately 2.8% of all 6,688 adverse event reports for this drug.
Patients taking DESVENLAFAXINE who experience completed suicide should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMPLETED SUICIDE is a less commonly reported adverse event for DESVENLAFAXINE, but still significant enough to appear in the safety profile.
In addition to completed suicide, the following adverse reactions have been reported for DESVENLAFAXINE:
The following drugs have also been linked to completed suicide in FDA adverse event reports:
COMPLETED SUICIDE has been reported as an adverse event in 186 FDA reports for DESVENLAFAXINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
COMPLETED SUICIDE accounts for approximately 2.8% of all adverse event reports for DESVENLAFAXINE, making it a notable side effect.
If you experience completed suicide while taking DESVENLAFAXINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.